期刊文献+

多拷贝脑钠肽基因表达质粒的构建及其表达 被引量:3

Construction and Expression of Recombinant Expression Vector for Multi-copy B-type Natriuretic Peptide Gene
在线阅读 下载PDF
导出
摘要 目的构建多拷贝脑钠肽(BNP)基因重组表达质粒,并探讨BNP基因的拷贝数与其表达水平的相关性。方法通过人工合成和PCR技术扩增BNP基因,将其克隆至载体pCW111中,构建表达质粒pBNP11,并通过亚克隆构建含有不同数量表达盒的正向串联表达质粒,分别转化大肠杆菌DH5α和BL21(DE3),经温度诱导表达,SDS-PAGE分析,并经激光扫描测定目的蛋白的表达量。结果测序及酶切鉴定证明1~3拷贝BNP重组表达质粒构建正确,重组蛋白在大肠杆菌DH5α和BL21(DE3)中均可获得表达,表达量分别为菌体总蛋白的8.12%、9.94%、和9.18%。结论已构建了多拷贝BNP的重组表达质粒,BNP的表达水平随BNP拷贝数的增加而升高,但并未成倍增加。 Objective To construct the recombinant expression vector for multi-copy B-type natriuretic peptide (BNP) gene and explore the relationship between the gene copy number and expression level. Methods BNP gene was amplified by PCR using synthetic primers and cloned into vector pCW111 to construct recombinant plasmid pBNP11, based on which a series of recombinant plasmids containing muhi-copy expression cassettes were constructed and transformed to E. coli DHSct and BL21 (DE3) separately for expression under thermal induction. The expressed product was identified by SDS-PAGE and determined for expression level by laser scanning. Results Both sequencing and restriction analysis proved that the recombinant plasmids containing 1-3 copy expression cassettes were constructed correctly. Recombinant BNP protein was expressed in both E. coli DH5ct and BL21 (DE3). The expressed products of recombinant plasmids containing 1, 2 and 3 copy expression cassettes contained 8. 12%, 9. 94% and 9. 18% of total somatic protein respectively. Conclusion The recombinant expression vector for muhi-copy B-type BNP gene was successfully constructed. The expression level of BNP increased, but not in proportion, with the increasing gene copy number.
出处 《中国生物制品学杂志》 CAS CSCD 2008年第12期1062-1065,共4页 Chinese Journal of Biologicals
基金 深圳大学科研启动基金资助项目(200711)
关键词 脑钠肽 质粒拷贝数 表达盒 原核表达 B-type natriuretic peptide(BNP) Plasmid copy number Expression cassette Prokaryotic expression
  • 相关文献

参考文献8

  • 1Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Cardilo,2001, 37(2): 379-385.
  • 2Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J, 2002, 144(5 ): 834-839.
  • 3ten Wolde M, Tulevski II, Mulder JW, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation, 2003, 107 (16): 2082-2084.
  • 4Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New Endl J Med, 2002, 347(3): 161-167.
  • 5Morrison LD, Harrison A,Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol, 2002, 39(2 ): 202-209.
  • 6Elkayam U, Akhter MW, Tummala P, et al. Nesiritide: a new drug for the treatment of decompensated heart failure. J Cardiovasc Pharmacol Ther, 2002, 7(3): 181-194.
  • 7巨年季,李卫鹏.BNP的临床应用价值(文献综述)[J].放射免疫学杂志,2004,17(4):308-310. 被引量:10
  • 8Kucher N, Printzen G, Goldhaber SZ, et al. Progostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation, 2003, 107(20): 2545-2547.

二级参考文献25

  • 1Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B - natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol.2002,39 (2) :202.
  • 2Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventric
  • 3Nagaya N, Nishikimi T, Goto Y, et al. Sustained elevation of plasma brain natriuretic peptide is a biochemical marker for the prediction of progrssive ventricular remodeling after acute myocardial infarction. Am Heart J. 1998,135:21.
  • 4Murdoch DR, Mcdonagh TA, Byme J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic andneuroendocrine effects of tailored versus empirical
  • 5Selvais PL, Donckier JE, Robert A, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest. 1998,
  • 6Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B - type natriuretic peptide in comparison with those of A - ytpe natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994,90 ( 1 ): 195.
  • 7Mcdonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998,351:9.
  • 8Sudoh T, Kangawa K, Minamino N, et al. A natnuretic peptide in porcine brain. Nature. 1988, 322:78.
  • 9Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B - type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol. 2001, 37(2) :379.
  • 10Klinge R, Hystad M, Kjek shus J, et al. An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. Scand J Clin Lab Invest. 1998, 58:683.

共引文献9

同被引文献48

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部